Abstract
Micro-RNAs (miRNA) are short non-coding sequences involved in the biological regulatory process. The miRNAs show a unique expression in diseases, resulting in pathogenesis. Identifying the novel compounds is interesting during this process. The miRNA is a biomarker that helps to detect cancer at an early stage through pathogenesis. Azobenzene and pyrazole are novel compounds, having a cytotoxic effect on cancer cells. These novel compounds are molecular probes used in breast cancer therapy. The viral-based systems have few limitations, such as toxicity and immunogenicity. Therefore, the non-viral based lipoplex and polyplex systems are attractive due to no size limitations for the transfection of micro RNAs. The conventional drug delivery systems have a large size and low drug efficacy at the target site. The nanoparticles prepared by nanoprecipitation methods are attractive in cancer therapy. Thus, the miRNA acts as a powerful tool and identifies the drug target in cancer therapy.
Keywords: micro RNA, drug target, bio-marker, drug discovery, drug delivery, small molecules, cancer therapy.
Current Drug Discovery Technologies
Title:Micro-RNA (miRNA): A Biomarker to Identify Novel Compounds in Drug Discovery and Delivery for Cancer Therapy
Volume: 18 Issue: 6
Author(s): Gokul Paramasivam*
Affiliation:
- Saveetha school of engineering, Department of biomedical engineering, Saveetha Institute of Medical & Technical Sciences (SIMATS), Saveetha Nagar, Thandalam, Chennai - 602 105, TamilNadu,India
Keywords: micro RNA, drug target, bio-marker, drug discovery, drug delivery, small molecules, cancer therapy.
Abstract: Micro-RNAs (miRNA) are short non-coding sequences involved in the biological regulatory process. The miRNAs show a unique expression in diseases, resulting in pathogenesis. Identifying the novel compounds is interesting during this process. The miRNA is a biomarker that helps to detect cancer at an early stage through pathogenesis. Azobenzene and pyrazole are novel compounds, having a cytotoxic effect on cancer cells. These novel compounds are molecular probes used in breast cancer therapy. The viral-based systems have few limitations, such as toxicity and immunogenicity. Therefore, the non-viral based lipoplex and polyplex systems are attractive due to no size limitations for the transfection of micro RNAs. The conventional drug delivery systems have a large size and low drug efficacy at the target site. The nanoparticles prepared by nanoprecipitation methods are attractive in cancer therapy. Thus, the miRNA acts as a powerful tool and identifies the drug target in cancer therapy.
Export Options
About this article
Cite this article as:
Paramasivam Gokul *, Micro-RNA (miRNA): A Biomarker to Identify Novel Compounds in Drug Discovery and Delivery for Cancer Therapy, Current Drug Discovery Technologies 2021; 18(6) : e130921188092 . https://dx.doi.org/10.2174/1570163817999201117114237
DOI https://dx.doi.org/10.2174/1570163817999201117114237 |
Print ISSN 1570-1638 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6220 |

- Author Guidelines
- Editorial Policies
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Allegations from Whistleblowers
- Publishing Ethics and Rectitude
- Increase Visibility Of Your Article
- Archiving Policies
- Reviewer Guidelines
- Guest Editor Guidelines
- Board Recruitment Workflow
- Short Guide
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
A Role of Immunotherapy in Metastatic Malignant Melanoma
Central Nervous System Agents in Medicinal Chemistry Heme Oxygenase-1 as a Target for the Design of Gene and Pharmaceutical Therapies for Autoimmune Diseases
Current Gene Therapy <I>Prunus Armeniaca L</I>. Seed Extract and Its Amygdalin Containing Fraction Induced Mitochondrial-Mediated Apoptosis and Autophagy in Liver Carcinogenesis
Anti-Cancer Agents in Medicinal Chemistry Beyond PD-1/PD-L1 Axis Blockade: New Combination Strategies in Metastatic Melanoma Treatment
Current Cancer Therapy Reviews Ghrelin: A Molecular Target for Weight Regulation, Glucose and Lipid Metabolism
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Anticancer Drug Combinations, How Far We can Go Through?
Anti-Cancer Agents in Medicinal Chemistry Reversal of Tumor Induced Dendritic Cell Paralysis: A Treatment Regimen Against Cancer
Current Immunology Reviews (Discontinued) Therapeutic Potential and Outlook of Alternative Medicine for Osteoporosis
Current Drug Targets In Silico Design of Protein Kinase Inhibitors: Successes and Failures
Anti-Cancer Agents in Medicinal Chemistry Self-Assembled Peptide Nanoarchitectures: Applications and Future Aspects
Current Topics in Medicinal Chemistry Chemotherapy Resistance in Breast Cancer
Current Cancer Therapy Reviews Encapsulation of Metal and Metal Oxide Nanoparticles by Nutraceuticals: Implications for Biological Activities
Current Nutraceuticals Recent Developments in the Mechanism of Anticancer Agents Based on Electron Transfer, Reactive Oxygen Species and Oxidative Stress
Anti-Cancer Agents in Medicinal Chemistry Correlation Between <i>BCL2</i> and <i>Mcl1</i> Single Nucleotide Polymorphisms and Chemotherapy Response in Jordanian Patients with Colorectal Cancer
Current Pharmaceutical Biotechnology Clinical Trials with Oncolytic Adenovirus in China
Current Cancer Drug Targets Evaluation of Changes in the Expression Profile of mRNA and Proteinencoding Adiponectin in Ishikawa Cell Line under the Influence of Cisplatin – Preliminary Report
Current Pharmaceutical Biotechnology The Delivery of Personalised, Precision Medicines <i>via</i> Synthetic Proteins
Drug Delivery Letters Current and Emerging Therapy for Malignant Pleural Mesothelioma: Focus on CD26/Dipeptidyl Peptidase IV as a Therapeutic Target
Current Cancer Therapy Reviews Molecular Mechanisms Involved in the Antitumor Activity of Isolated Lectins from Marine Organisms: A Systematic Review
Current Drug Targets Developmental Expression and Dysregulation of miR-146a and miR-155 in Down's Syndrome and Mouse Models of Down's Syndrome and Alzheimer's Disease
Current Alzheimer Research